Pular para o conteúdo
VuFind
    • English
    • Deutsch
    • Español
    • Français
    • Italiano
    • 日本語
    • Nederlands
    • Português
    • Português (Brasil)
    • 中文(简体)
    • 中文(繁體)
    • Türkçe
    • עברית
    • Gaeilge
    • Cymraeg
    • Ελληνικά
    • Català
    • Euskara
    • Русский
    • Čeština
    • Suomi
    • Svenska
    • polski
    • Dansk
    • slovenščina
    • اللغة العربية
    • বাংলা
    • Galego
    • Tiếng Việt
    • Hrvatski
    • हिंदी
    • Հայերէն
    • Українська
    • Sámegiella
    • Монгол
Avançada
  • Clonal heterogeneity in differ...
  • Citar
  • Enviar por SMS
  • Enviar por e-mail
  • Imprimir
  • Exportar registro
    • Exportar para RefWorks
    • Exportar para EndNoteWeb
    • Exportar para EndNote
  • Link permanente
Clonal heterogeneity in differentiation response and resistance to the IDH2 inhibitor enasidenib in acute myeloid leukemia

Clonal heterogeneity in differentiation response and resistance to the IDH2 inhibitor enasidenib in acute myeloid leukemia

Detalhes bibliográficos
Principais autores: Quek, L, David, M, Kennedy, A, Metzner, M, Amatangelo, M, Shih, A, Stoilova, B, Karamitros, D, Quivoron, C, Heiblig, M, Willekens, C, Saada, V, Peniket, A, Bernard, O, Agresta, S, Yen, K, Stein, E, De Botton, S, Thakurta, A, Levine, R, Penard-Lacronique, V, Vyas, P
Formato: Conference item
Publicado em: American Society of Hematology 2017
  • Itens
  • Descrição
  • Registros relacionados
  • Registro fonte

Registros relacionados

  • Clonal heterogeneity of acute Myeloid Leukemia treated with the IDH2 inhibitor Enasidenib
    por: Vyas, P, et al.
    Publicado em: (2018)
  • Enasidenib induces acute myeloid leukemia cell differentiation to promote clinical response
    por: Amatangelo, MD, et al.
    Publicado em: (2017)
  • Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia
    por: Stein, EM, et al.
    Publicado em: (2017)
  • Somatic gene mutation patterns and burden influence outcomes with enasidenib in relapsed/refractory IDH2-mutated AML
    por: Risueño, A, et al.
    Publicado em: (2024)
  • Molecular features associated with response to enasidenib plus azacitidine in newly diagnosed IDH2-mutated acute myeloid leukemia
    por: Risueño, A, et al.
    Publicado em: (2023)

Opções de Busca

  • Histórico de buscas
  • Busca Avançada

Encontrar Mais

  • Navegar o acervo
  • Navegar por ordem alfabética
  • Explorar canais
  • Bibliografia Recomendada
  • Novos itens

Precisa de ajuda?

  • Dicas de Busca
  • Serviço de Referência
  • Perguntas Frequentes